LGND
Ligand Pharmaceuticals Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +13.3% ·
share flow +5.4% ·
net new positions +5.9%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | -1 | 13.55K | $4.18M | n/a | −1 |
| Q2 2026 | 111 | +8 | 14.86M | $4.69B | +14 | −6 |
| Q1 2026 | 106 | -5 | 14.62M | $2.92B | +4 | −9 |
| Q4 2025 | 110 | 0 | 15.70M | $2.97B | +1 | −1 |
| Q3 2025 | 17 | +2 | 7.48M | $1.32B | +3 | −2 |
| Q2 2025 | 13 | 0 | 6.47M | $735.39M | +3 | −3 |
| Q1 2025 | 10 | +3 | 1.36M | $143.17M | +3 | n/a |
| Q4 2024 | 7 | -2 | 1.36M | $145.21M | n/a | −2 |
| Q3 2024 | 8 | -2 | 597.13K | $59.78M | n/a | −2 |
| Q2 2024 | 10 | n/a | 659.66K | $55.58M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.88M | -1.0% | $510.97M | 0.0% | ▼ Trim | 2 | SEC ↗ ×15 |
| 2 | The Vanguard Group ✦ (passive) | 2.08M | -0.6% | $367.79M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 749.36K | -0.1% | $132.74M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 474.19K | -3.0% | $84.01M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 5 | Fidelity (FMR) ✦ | 457.23K | +1643.6% | $80.99M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Goldman Sachs Group ✦ | 367.80K | n/a | $65.15M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Morgan Stanley ✦ | 188.70K | n/a | $33.43M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 8 | Fisher Asset Management ✦ | 108.93K | +2.7% | $19.30M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | JPMorgan Chase ✦ | 79.44K | n/a | $14.07M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 10 | T. Rowe Price ✦ | 18.91K | +5.3% | $3.35M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 17.51K | +144.9% | $3.10M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 16.70K | New | $2.96M | 0.0% | New | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 13.31K | -68.2% | $2.36M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 14 | Gotham Asset Management ✦ | 9.47K | New | $1.68M | 0.0% | New | 1 | SEC ↗ |
| 15 | Wellington Management ✦ | 8.32K | +12.8% | $1.47M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | AQR Capital Management ✦ | 4.58K | +36.5% | $812,010 | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 17 | Bridgewater Associates ✦ | 1.29K | New | $228,156 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $2.96M | 0.0% |
| Gotham Asset Management | $1.68M | 0.0% |
| Bridgewater Associates | $228,156 | 0.0% |
Exited
| Norges Bank | $1.60M | was 0.0% |
| Tweedy, Browne | $356,955 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 353 holders, 20.71M shares, $4.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 235 sh · $72,190
Officer · 404 sh · $123,698
Officer · 17 sh · $5,232
Officer · 1.53K sh · $467,431
Officer · 1.98K sh · $599,804
Officer · 833 sh · $251,991
Director · 1.20K sh · $342,000
Officer · 385 sh · $110,697
Officer · 300 sh · $85,196
Officer · 1.80K sh · $513,301
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology